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Human ornithine aminotransferase complexed with L-canaline
and gabaculine: structural basis for substrate recognition
Sapan A Shah1, Betty W Shen1 and Axel T Brünger1,2*
Background: Ornithine aminotransferase (OAT) is a 45 kDa pyridoxal-5′-
phosphate (PLP)-dependent enzyme that catalyzes the conversion of L-ornithine
and 2-oxoglutarate to glutamate-δ-semialdehyde and glutamic acid,
respectively. In humans, loss of OAT function causes an accumulation of
ornithine that results in gyrate atrophy of the choroid and retina, a disease that
progressively leads to blindness. In an effort to learn more about the structural
basis of this enzyme’s function, we have determined the X-ray structures of
OAT in complex with two enzyme-activated suicide substrates: L-canaline, an
ornithine analog, and gabaculine, an irreversible inhibitor of several related
aminotransferases.
Results: The structures of human OAT bound to the inhibitors gabaculine and
L-canaline were solved to 2.3 Å at 110K by difference Fourier techniques. Both
inhibitors coordinate similarly in the active site, binding covalently to the PLP
cofactor and causing a 20° rotation in the cofactor tilt relative to the ligand-free
form. Aromatic–aromatic interactions occur between the bound gabaculine
molecule and active-site residues Tyr85 and Phe177, whereas Tyr55 and
Arg180 provide specific contacts to the α-amino and carboxyl groups of L-
canaline.
Conclusions: The OAT–L-canaline complex structure implicates Tyr55 and
Arg180 as the residues involved in coordinating with the natural substrate
ornithine during normal enzyme turnover. This correlates well with two enzyme-
inactivating point mutations associated with gyrate atrophy, Tyr55→His and
Arg180→Thr. The OAT–gabaculine complex provides the first structural
evidence that the potency of the inhibitor is due to energetically favorable
aromatic interactions with residues in the active site. This aromatic-binding
mode may be relevant to structure-based drug design efforts against other ω-
aminotransferase targets, such as GABA aminotransferase.
Introduction
Aminotransferases are enzymes that catalyze the transfer
of amino groups from amino acids to oxoacids. Collec-
tively, they make up a group of homologous proteins [1]
that share a similar vitamin B6-dependent mechanism.
Ornithine aminotransferase (OAT, L-ornithine:2-oxoacid
aminotransferase, EC 2.6.1.13) is a 45 kDa enzyme that
catalyzes the transfer of the δ-amino group of L-ornithine
to 2-oxoglutarate. The metabolic importance of OAT in
regulating ornithine levels is underscored by the fact that
deficiencies of the enzyme in humans result in hyperor-
nithinemia, a condition that leads to gyrate atrophy of
the choroid and retina which progressively causes blind-
ness [2]. OAT is distinct from other aminotransferases,
for which there is detailed structural and mechanistic
information [3], in that it is specific for an amino group
other than the carboxyl bearing α-amino group. Another
member of the same subgroup of aminotransferases [4] is
γ-aminobutyric acid aminotransferase (GABA-AT), an
enzyme whose substrate is the brain’s major inhibitory
neurotransmitter. In addition to having high sequence
homology, OAT and GABA-AT also share a common
inhibitory mechanism [5], a fact that has complicated
efforts to design inhibitors that selectively inactivate
GABA-AT [6].
The transamination cycle in pyridoxal phosphate (PLP)--
dependent enzymes can be divided into two half reac-
tions. In the case of OAT, the first half reaction begins
with ornithine binding in the active site where the
Schiff-base linkage between the PLP cofactor and Lys292
is transferred to the δ-amino group of ornithine. Follow-
ing deprotonation and hydrolysis at the δ-carbon of
ornithine, glutamate-γ−semialdehyde is released, leaving
the cofactor with an amino group bound to it as pyridox-
amine-5′-phosphate (PMP). The second half reaction is a
reversal of the first, with 2-oxoglutarate binding and
reacting with the PMP cofactor, yielding L-glutamic acid
and regenerating the Schiff base between the PLP and
active site Lys292. In order to learn more about the
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structural basis for substrate recognition, it is useful to
capture the enzyme in a stable intermediate state within
the transamination cycle for the purposes of crystallo-
graphic analysis. Enzyme activated irreversible inhibitors
are ideal for this purpose, because they function by a
mechanism requiring partial catalytic turnover by the
enzyme that leads to a stable dead-end intermediate. 
L-gabaculine (5-amino-1,3-cyclohexadienyl carboxylic acid)
is a naturally occurring irreversible inhibitor of GABA-
AT [7] (Figure 1). Because of the nearly identical mecha-
nisms of transamination between OAT and GABA-AT,
as well as the similarity of their substrates, it was found
that gabaculine is an equally potent irreversible inhib-
itor of OAT [5]. Gabaculine’s mechanism of action is
somewhat unique in that it involves generation of an aro-
matic compound. After gabaculine binds to the active
site of OAT and forms a Schiff base with the PLP cofac-
tor, a hydrogen is removed from the imino bearing
carbon of the inhibitor, as it would be from the natural
substrate ornithine. In the case of gabaculine, however,
hydrogen abstraction at the β-carbon position leads to an
unstable intermediate that is converted to m-carboxy-
phenylpyridoxamine phosphate, an extremely stable and
irreversible aromatic modification of the cofactor [7]
(Figure 2). 
A structural analogue of L-ornithine, L-canaline (α-amino-
γ−amino-oxybutyric acid), has also been shown to be a
strong inhibitor of OAT [8] (Figure 1). It inhibits the
enzyme by forming a stable oxime with the PLP cofactor
via its γ-aminooxy group (Figure 2b). Although L-canaline
is a reversible competitive inhibitor of aspartate amino-
transferase, it is irreversible with respect to OAT. This
specificity is thought to be the result of the similar interac-
tions that ornithine and L-canaline make between their α-
amino and carboxyl groups and the active site of OAT [9].
The actual residues involved in these contacts, however,
until now have not been known.
We present here the crystal structures of OAT in com-
plex with gabaculine and L-canaline refined to 2.3 Å, al-
lowing detailed analysis of the specific residues involved
in inhibitor binding. In the case of gabaculine, we find
that aromatic–aromatic interactions between active-site
residues and the bound inhibitor play a significant role in
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Figure 1
Substrate and inhibitor chemical structures.
Chemical structures of (a) L-Ornithine, 
(b) α-amino-γ-amino-oxybutyric acid (L-
canaline) and (c) 5-amino-1,3,-cyclohexadienyl
carboxylic acid (gabaculine).COO-
       NH2
+H3N COO-+H3N
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Figure 2
Irreversible inhibitor–cofactor intermediate structures. Chemical
structures of the irreversible intermediates generated upon binding of
(a) gabaculine  and (b) L-canaline to pyridoxal phosphate.
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the inhibitor’s potency. The L-canaline complex allowed
the specific residues involved in coordinating with the α-
amino and carboxyl groups to be determined. The role of
these active-site residues in the recognition of the natu-
ral substrate, L-ornithine, and their correlation with two
inherited mutations in OAT that result in gyrate atrophy
in humans are also discussed.
Results and discussion
Structure determination
Complexes of ornithine aminotransferase both with L-cana-
line and gabaculine were obtained by co-crystallization of
protein that had been pre-incubated with inhibitor. Dif-
fraction data, using glycerol as cryo-protectant, were collec-
ted at 110K on each respective protein–inhibitor complex
(Table 1). Both complexes crystallized in the same space
group (P3221) and has similar overall unit cell dimensions
as native OAT crystals [10]. The co-crystal data were
phased by difference Fourier techniques using the struc-
ture of native OAT, solved to 2.5 Å (BWS, M Hennig, E
Hohenester, T Schirmer and JN Janionius, unpublished
data). The asymmetric unit in both native and inhibitor-
bound complex crystals consists of three OAT protomers
(one and a half dimers) related by a noncrystallographic
threefold axis [11]. An initial model consisting of three
OAT protomers, with no PLP or inhibitor atoms, was
subjected to rigid-body minimization and torsion-angle
dynamics [12] against the inhibitor-bound data. Fo–Fc
difference maps using phases from this ligand-free
model, clearly showed the presence of inhibitor and
cofactor density within the active site of both the OAT–
gabaculine and OAT–L-canaline complexes (Figure 3).
After the addition of inhibitor and cofactor atoms, several
rounds of rebuilding into composite annealed omit maps
was carried out, which allowed misplaced sidechain and
backbone atoms to be properly positioned. Statistics for
the final models are given in Table 2. In the following
sections, all structural analysis and calculations were
made using only one of the three protomers in the
asymmetric unit.
Overall structure and domain movement
A single asymmetric unit in the OAT–inhibitor complex
structures consists of one and a half dimers of OAT rela-
ted by a threefold noncrystallographic symmetry. Although
the protein is active as a dimer, each monomer has its own
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Table 1
Data collection statistics.
Inhibitor Gabaculine Canaline
X-ray source, λ (Å) CHESS, 0.9417 CHESS, 0.9417
Space group P3(2)21 P3(2)21
Unit cell a,b,c (Å) 115.0, 115.0, 185.7 115.9, 115.9, 185.7
Resolution range (Å) 50.0–2.3 50.0–2.3
Unique reflections 57,010 56,813
Rmerge (%)* 6.4 (17.1) 9.8 (18.2)
Completeness (%) 89.9 (80.1) 87.4 (66.3)
Redundancy 4.6 (2.6) 4.3 (3.1)
*Rmerge = ΣhklΣi | < I(hkl) > –I(hkl)i | / Σhkl < I(hkl) >, where I(hkl)i is the
measured diffraction intensity and < I(hkl) > equals the mean value of
intensity. Values indicated in parentheses are for the highest resolution
shell (2.4–2.3 Å).
Figure 3
Omit density map. Fobs–Fcalc(omit) density is shown contoured at 2σ,
superimposed on the final refined coordinates of the PLP cofactor and
(a) gabaculine inhibitor or (b) L-canaline. Calculated structure factors
used for the map calculation were obtained from a preliminary model in
which the inhibitor and PLP cofactor were omitted from refinement.
Atoms are shown in standard colors.
active site with numerous contacts between adjacent active
sites in the dimer. Each OAT monomer can be subdi-
vided into three domains — an N-terminal segment, a
small C-terminal domain and a large PLP-binding domain.
The active site of the enzyme is centered around the PLP
cofactor, and it is located in the cleft between the large
and small domains of the protein (Figure 4). This type of
fold is common among several PLP-dependent enzymes,
including dialkylglycine decarboxylase and aspartate
aminotransferase [11]. It was of interest to this study
whether OAT undergoes a significant conformational
change upon ligand binding, similar to that observed for
aspartate aminotransferase (AAT) in which a 13° rotation
of the small C-terminal domain towards the large PLP-
binding domain is observed [13]. Superposition of the
refined Cα coordinates of each inhibitor-bound complex
on the ligand-free native structure reveals no significant
bulk domain movements. The OAT–L-canaline complex
does exhibit a slightly more open conformation with res-
pect to the gabaculine-bound complex, however. In order
to quantitate the extent of domain closure in the gabacu-
line complex, a difference distance matrix analysis was
employed [14]. In such an analysis, a matrix containing all
the intra-atomic Cα distances of a protein is subtracted
from an identical matrix of an identical or related protein.
This type of comparison is independent of the relative
rotation or translation of the two coordinate sets and thus
is not biased by the method in which the two structures
are overlaid. The final plot of subtracted matrices gives
the actual distance that the α-carbon of each residue has
moved in relation to every other residue. The difference
distance matrix plot between the canaline- and gabacu-
line-bound OAT structures (Figure 5), suggests that
changes in Cα positions between the two structures occur
mainly in three regions that correspond to the three
domains of the enzyme: residues 38–116, residues 117–
342 and residues 343–438. In both complexes, there is no
change in the Cα positions between residues belonging
to the same domain (intradomain movement, diagonal
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Table 2
Refinement statistics*.
Inhibitor Gabaculine Canaline
Resolution range (Å) 50.0–2.3 (2.4–2.3) 50.0–2.3 (2.4–2.3)
Reflections F > 2σ 52,218 (5123) 54,425 (4654)
Number of atoms (non H) 9525 9525
Bulk solvent parameters
ksol (electrons / Å3) 0.4324 0.3735
Bsol (Å2) 44.34 47.44
Rfree (%)† 23.48 (28.88) 23.66 (29.55)
Rcryst(%)† 20.63 (25.81) 20.99 (26.16)
Number of waters 329 276
Rmsd bond length (Å) 0.007 0.007
Rmsd bond angle (°) 1.320 1.322
Average B factor (Å2)
water atoms 24.04 31.29
protein atoms 22.5 28.71
Ramachandran plot
most favored regions (%) 85.5 86.2
allowed regions (%) 13.6 12.9
*Values indicated in parentheses are for the highest resolution shell
(2.4–2.3 Å). †Rcryst = Σhkl | |Fobs (hkl)|–k| Fcalc(hkl)| | / Σhkl |Fobs(hkl)|;
Rfree = Rcryst for a test set of reflections not used during refinement
(10% for both complexes).
Figure 4
(a) (b)
Overall structure and inhibitor-binding cleft. (a) Ribbon diagram of the
OAT–gabaculine complex. OAT is colored with respect to each of its
three domains, the N-terminal domain (blue), PLP-binding domain (red)
and the C-terminal domain (green). The gabaculine–PLP cofactor
complex, which resides in a cleft between the three domains, is shown
in ball-and-stick representation (standard colors). (b) Stereo pair of the
α-carbon trace of the OAT–gabaculine complex. Cα positions are
labeled every twenty residues. (Figures prepared using MOLSCRIPT
version 1.4 [30].)
boxes in Figure 5). In contrast, the N- and C-terminal
small domains appear to have moved slightly closer to the
large PLP-binding domain in the gabaculine-bound struc-
ture (off-diagonal boxes in Figure 5). The approximate
distance involved in the movement is shown to be be-
tween 0–1.2 Å. Although it is interesting that there is
some flexibility in the relative orientation of the three
domains of OAT, the distances involved are small and
may be due to ‘breathing’ motions or packing effects
resulting from differences in unit cell dimensions
between the two complexes. 
PLP-cofactor tilt
The conformation of the active site in inhibitor-free OAT
is shown in Figure 6 (green). The PLP cofactor is cova-
lently bound via a Schiff base to Lys292. Located above
the PLP cofactor is a pocket that is flanked on three sides
by aromatic residues, Tyr85, Phe177 and Tyr55. The sub-
strate-binding site is in this pocket. Several residues from
the adjacent monomer in the OAT dimer border the
active site, including Thr322* (residues in the adjacent
protomer will hereafter be indicated with an *). Several
local sidechain conformational changes occur upon ligand
binding that are consistent in both the gabaculine- and L-
canaline-bound models. The most obvious changes occur
in response to transfer of the internal Schiff base from
Lys292 to the inhibitor. Once the Schiff base with the
pyridoxal-5′-phosphate cofactor is broken, Lys292 is free
to form a hydrogen bond with the sidechain of Thr322*.
In addition, the PLP cofactor undergoes a rotation away
from Lys292 and towards Phe177 (Figure 6, yellow). The
degree of PLP rotation relative to the inhibitor-free struc-
ture differs between the two OAT–inhibitor complexes,
with a 27¼ tilt induced in the gabaculine complex and a
21¼ rotation with the canaline complex. The 5′ phosphate
and ring nitrogen of the cofactor remain relatively fixed,
with the rotation induced mainly by torsions about the
O5′–P and C5′–O5′ bonds. Phe177 which lies above the
plane of the cofactor must also shift to accommodate the
PLP movement. Specifically, its sidechain is forced to
rotate about χ1 by 10°, corresponding to 1.3 Å movement
of the phenyl ring centroid.
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Figure 5
Difference distance matrix plot between the
OAT–L-canaline and OAT–gabaculine
complexes. The matrix calculation is over the
Cα coordinates of residues 38–438 of each
respective OAT–inhibitor complex. Positive
differences, which correspond to a
compacting of the gabaculine structure
relative to the L-canaline structure, are given in
increasing shades of purple. Negative
differences are in red. Dotted lines indicate
the domain boundaries. Boxes on the diagonal
represent intradomain movement. Off-diagonal
boxes represent interdomain movements. See
text for interpretation. (Plot made using the
DDMP program from the Center of Structural
Biology, Yale University, New Haven, CT,
USA.) 
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Gabaculine-binding mode: favorable aromatic interactions
In the ligand-bound form of OAT, the amine group of
gabaculine is bound to the cofactor via a Schiff base,
whereas one of the carboxyl oxygen atoms O7A forms a
strong hydrogen bond with Tyr55 (Figure 6). Two interac-
tions occur between the inhibitor carboxylate head group
and residues in the adjacent monomer — a weak hydro-
gen bond between the backbone amide hydrogen of
Ser321* and the other carboxyl oxygen atom O7 of the
inhibitor (shown in Figure 7a) and a water mediated
linkage between carboxyl oxygen O7A and the backbone
amide of Arg113* (not shown). Hydrogen bonds between
the carboxyl group of gabaculine and active-site residues
help to position the inhibitor properly for Schiff-base for-
mation with the PLP. Although the carboxyl head is the
only functional group that gabaculine presents to the
active site, the OAT–gabaculine crystal structure reveals
an additional important interaction. Hydrogen abstraction
from the bound inhibitor occurs at the carbon position
adjacent to the Schiff base, which is analogous to that
undergone by the natural substrate, ornithine. When gaba-
culine is bound, however, a second hydrogen abstraction
at the β-carbon position leads to formation of an aromatic
intermediate, m-carboxyphenyl pyridoxamine phosphate
(mCPP) (Figure 2a) [15]. The structural basis for the
strong binding of mCPP is evident from the residues that
border the substrate binding pocket. Tyr85 is stacked in a
near parallel fashion approximately 4.1 Å above the plane
of the intermediate, whereas Phe177 is stacked at a nearly
orthogonal angle on the opposite side of the intermediate,
such that there is a distance of 5.2 Å between the ring
centers of Phe177 and the inhibitor (Figure 7a). Favorable
interactions such as these between aromatic protein
residues are well documented, with a preferential distance
between aromatic ring centers being 4.5–7 Å and relative
angle between ring planes approaching 90° [16]. Monte
Carlo simulations of benzene predict the tilted T arrange-
ment and the parallel stacked and displaced arrangement
to be two favorable conformations for benzene dimers,
with interaction energies of –2.31 and –2.15 kcal/mol
respectively [17]. These predicted conformations are very
similar to the observed arrangements between Tyr85,
Phe177 and the aromatic gabaculine intermediate in the
crystal structure of OAT–gabaculine. The expected con-
tribution to binding energy of approximately 4 kcal/mol
that is donated by aromatic–aromatic interactions with
active-site residues, provides the structural basis for why
the OAT-catalyzed conversion of non-aromatic gabaculine
to mCPP produces a dead-end irreversible intermediate. 
Canaline binding: Arg180 and Tyr55
Although L-Canaline binds in the same pocket as gabacu-
line, it presents different functional groups to the active
site. Like the natural substrate L-ornithine, L-canaline
offers both an α-amino and a carboxyl group that are rec-
ognized by the enzyme. In the OAT–canaline crystal
structure, the inhibitor carboxyl group coordinates with
Arg180 and the backbone amide hydrogen of Ser321*
(Figure 7b). The α-amino group of canaline forms a strong
hydrogen bond with Tyr55, the same residue that bonds
to the carboxyl group of the inhibitor in the OAT–gabacu-
line complex structure. No conformational change in the
backbone of the enzyme is required to position these
residues in the optimal orientation for coordination with
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Figure 6
Stereoview of the conformational changes in
OAT produced by gabaculine binding. Final
model of the gabaculine-bound active site
(yellow) superimposed on the ligand-free
active site (green). Major conformational
changes incurred upon inhibitor binding
include a 27¼ rotation in PLP-cofactor tilt,
and a corresponding 1.3 Å movement of
Phe177. In addition, Lys292 forms a salt
bridge with Thr322*, a residue located on an
adjacent protomer in the OAT dimer.
Hydrogen bonds are indicated with dashed
lines. See text for discussion. 
the inhibitor. The γ-aminooxy group of canaline is bound
to the aldehyde position of the PLP cofactor via a stable
oxime. The effect of this inhibitor on other aminotrans-
ferases has been studied and, in particular, it was found
that L-canaline is a reversible non-competitive inhibitor of
aspartate aminotransferase (AAT) [9]. The specificity of L-
canaline as an irreversible inhibitor for OAT is a direct
result of its similarity to ornithine. The active site of OAT,
which has evolved to be selective for the δ-amino group,
requires a strong coordination site to sequester the more
reactive α-amino group and the adjacent carboxyl. In its
inhibition of OAT, L-canaline takes advantage of these
specific contacts. Oxime formation alone by canaline is not
sufficient to cause irreversible inhibition of AAT. Oxime
formation, in cooperation with specific contacts to Tyr55
and Arg180, make canaline inhibition of OAT irreversible. 
Arg180 and Tyr55: implications for L-ornithine
The orientation of canaline in the active site of OAT, as
well as the inhibitor’s similarity to the natural substrate
ornithine, implicate Tyr55 and Arg180 as the residues
involved in positioning ornithine in the active site for spe-
cific transamination at the δ position. The role of Tyr55
and Arg180 as active site residues that are essential for sub-
strate turnover is supported by genetic evidence gathered
from humans suffering from gyrate atrophy. Gyrate atrophy
of the choroid and retina, an inherited disease in humans
characterized by elevated ornithine levels, has been shown
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Figure 7
Stereoview of the inhibitor-bound active sites.
(a) Gabaculine and (b) L-canaline are
covalently bound to the PLP cofactor within
the active site of OAT. Residues marked with
* are located on an adjacent protomer in the
OAT dimer. Hydrogen bonds are indicated
with dashed lines. Of particular interest in (a)
is the aromatic ‘sandwich’ made by residues
Tyr85 and Phe177 around the aromatic
gabaculine inhibitor. The active-site residues
involved in hydrogen bonding to the
carboxylate and amino groups of L-canaline
are shown in (b). Both of these residues,
Tyr55 and Arg180, are found to be among
those mutated in patients suffering from
gyrate atrophy, see text for discussion. 
to be caused by deficiencies in OAT [2]. Sequence analysis
of the OAT genes from patients with gyrate atrophy
revealed 21 different mutant OAT alleles, 18 of which
result in single amino acid changes in the enzyme [18].
Both Tyr55 and Arg180 are found to be mutated in patients
suffering from gyrate atrophy. The observed phenotype of
the two mutations, Tyr55→His and Arg180→hr, were
tested in terms of mRNA expression levels and antigen
response. Although the phenotype of the Tyr55→His
mutation could not be determined due to compound het-
erozygosity, the Arg180→Thr mutant exhibited no change
in mRNA levels and was one of only two mutations that
abolished enzyme activity and exhibited no change in
antigen response [18]. On the basis of the OAT–inhibitor
complex structures, we conclude that the Tyr55His and
Arg180Thr mutations may alter the affinity for substrate by
disrupting the specific contacts that are necessary to posi-
tion ornithine in the active site. These mutations would not
prohibit binding of ornithine, as the substituted residues do
not cause steric clashes, but instead they would affect the
binding affinity by disrupting hydrogen bonds required to
position the substrate.
Biological implications
Ornithine aminotransferase (OAT) catalyzes a reaction
in the pathway that interconverts ornithine and proline,
and also serves to connect the urea and citric acid cycles.
Loss of OAT function in humans produces elevated
levels of ornithine that can lead to gyrate atrophy (GA) of
the choroid and retina, an inherited disease that results in
blindness [2]. OAT is in the same subgroup as some other
aminotransferases that also have key metabolic roles.
This subgroup includes γ-aminobutyric acid aminotrans-
ferase (GABA-AT), an enzyme whose substrate is the
brain’s major inhibitory neurotransmitter, and glutamate-
1-semialdehyde aminotransferase (GSA-AT), an essen-
tial enzyme in the tetrapyrrole synthesis pathway in
plants. It is therefore of interest to learn more about the
mechanism of enzymes in this subgroup and, in particu-
lar, identify the residues that are involved in substrate
binding. Because loss of OAT function results in disease
in humans, the enzyme is not a focus for rational inhibitor
design. GABA-AT and GSA-AT, which are homologous
to OAT, however, are targets for selective inactivation.
Therefore, any information on the mechanism of inhibi-
tion with respect to OAT is relevant to rational drug
design efforts on these other more attractive targets. 
The inhibitor compounds, L-canaline and gabaculine, co-
crystallized with OAT in this study, mimic the natural
substrate well enough to bind to the active site of the
enzyme and undergo the first steps of the transamination
reaction. Unlike ornithine, however, they produce irre-
versible covalent intermediates with the PLP cofactor
(bound in the OAT active site) that cripple the enzyme.
Because L-canaline is virtually identical to ornithine, the
structure presented here provides information on the
specific residues in the active site that are involved in
substrate recognition. In particular, the OAT–L-canaline
complex reveals two residues, Tyr55 and Arg180, which
donate the specific contacts necessary to position
ornithine in the active site. These same residues have
been found to be mutated in patients suffering from GA
[18]. The structure presented here indicates that the
mutated OAT in GA would be unable to bind the sub-
strate ornithine, resulting in no enzymatic turnover.
GABA-AT and GSA-AT have a high sequence homol-
ogy with OAT and are inactivated by common inhibitors,
one of which is gabaculine. The mechanism by which
this inhibitor operates has been well documented [5,7,15],
and it proceeds by generating a stable aromatic interme-
diate. The crystal structure of OAT in complex with
gabaculine provides the first structural evidence that the
potency of the inhibitor is due to favorable aromatic–aro-
matic interactions with active-site residues. In particular,
we see two aromatic residues, Tyr85 and Phe177, that
sandwich the bound gabaculine. This type of interaction
may play a role in modulating gabaculine’s binding affin-
ity in these related aminotransferases, and thus may be
useful for future structure-based drug design efforts. 
Materials and methods
Crystallization and data collection
Recombinant human ornithine aminotransferase was expressed in
Escherichia coli, purified and crystallized under conditions similar to
those described previously [10]. L-canaline and gabaculine were pur-
chased from Sigma Chemical Co. and Fluka Chemical Corp., respec-
tively. Purified OAT was pre-incubated with the appropriate inhibitor prior
to crystallization at a 1:1 molar ratio. Crystals of each respective complex
were obtained by the hanging-drop vapor diffusion method and grew to
maximum size in about 1 weeks time. Following serial transfer to a mother
liquor containing 25% glycerol, selected crystals were flash frozen in
liquid propane and stored in liquid nitrogen until data collection. Diffrac-
tion data were collected on the A1 beam line at the Cornell High Energy
Synchrotron Source (CHESS) at 110K. For each complex, data were
recorded from a single crystal on a Princeton 2K CCD detector. Each
data set was processed and scaled with DENZO and SCALEPACK
[19]. For the OAT–L-canaline and OAT–gabaculine complex, data are,
respectively, 89.9% and 87.4% complete to 2.3 Å (Table 1).
Structure determination and refinement
Crystals of both OAT–inhibitor complexes were of the same space
group and had similar unit cell dimensions [10] as those of the native
structure, which consists of three OAT monomers related by non-crys-
tallographic symmetry (ncs) (BWS, M Hennig, E Hohenester, T
Schirmer and JN Janionius, unpublished data). An initial model for the
complex structures was obtained by rigid-body conjugate gradient
refinement of the native monomers with the PLP cofactor removed,
against the appropriate inhibitor bound data. All refinements, which
used data with amplitudes greater than 2s and 10% of the observed
reflections randomly removed for cross validation, were carried out with
the programs X-PLOR [20] and the developmental program CNS (Crys-
tallography and NMR System). Rigid-body minimization was followed by
a simulated annealing refinement protocol [12,21] consisting of the fol-
lowing steps (ncs restraints [22] were applied to the three monomers
throughout the refinement, as dictated by the free R value). Step 1:
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initial 100 steps of conjugate-gradient minimization without the X-ray
term but including harmonic restraints on the Ca coordinates in order to
regularize the backbone geometry. Step 2: 1000 steps of constant tem-
perature torsion-angle molecular dynamics [12] at 5000K. Step 3: 120
steps of all-atom molecular dynamics at 300K. Step 4: final 200 steps
of Powell conjugate-gradient minimization. Steps 2 to 4 were carried out
with the X-ray term included. The resulting model was used to compute
sA [23] weighted and Fo–Fc maps, in which density for the PLP cofac-
tor and respective inhibitor was clearly visible. The inhibitor and PLP
cofactor atoms were built into the density of these maps using the
program O [24]. These models were used to generate model-bias
reduced composite annealed omit maps (see next section), into which
minor sidechain and backbone errors, many of which were flagged by
PROCHECK [25], were rebuilt. After repeating the refinement protocol
described, restrained atomic B factor refinement was carried out with
target deviations placed on atoms forming bonds and angles. Water
molecules were automatically picked by searching difference maps for
peaks greater than 2s that were between 2.2 and 4.0 Å away from a
hydrogen-bond donor or acceptor. Two rounds of automatic water
picking were carried out, first using 2Fo–Fc maps, and second against
Fo–Fc maps. Each round included visual inspection of the electron
density of each picked water, followed by positional and B-factor refine-
ment. Water molecules with refined B factors greater than 60 Å2 were
removed. Towards the later stages of refinement, a bulk solvent correc-
tion [26] was included which allowed all observed data to be used in
refinement and map calculations. Throughout the course of model build-
ing and refinement, decrease in the crystallographic free R value [27]
was used as a monitor for progress. The steps involved in refinement of
the OAT–gabaculine and OAT–canaline complexes were carried out in
an identical fashion. Statistics for the final models, which include a ‘flat’
bulk solvent correction [26], are given in Table 2. 
Composite annealed omit maps
Composite annealed omit maps were used in the refinement process to
guide model building. These maps are a combination of several tech-
niques [22,28,29]. To create such a map, a region of the unit cell is first
partitioned into cubic volumes covering the protein. The subset of atoms
in a given volume plus a surrounding ‘cushion’ is deleted. The remaining
‘neutral volume’ atoms (those outside of the selected volume and sur-
rounding cushion [28]) are refined (simulated annealing refinement start-
ing at 400K followed by conjugate gradient minimization [29]) and used
to compute a σA weighted [23] electron-density map of the omitted
region. The complete map covering the protein is obtained by combining
the partial maps generated from each omitted cube volume excluding
the cushion. The width of each cubic volume for the maps computed
here was set to 25 Å. A cushion of 5 Å surrounded each volume and har-
monic positional restraints were applied to the atoms within a 2.0 Å
buffer surrounding this cushion. Forty initial minimization steps followed
by 100 steps of molecular dynamics at 400K and 20 steps of conjugate
gradient minimization were performed for each cube refinement.
Accession numbers
The atomic coordinates for OAT in complex with L-canaline and gabac-
uline have been deposited in the Brookhaven Protein Data Bank with
the code numbers 2can and 1gbn, respectively.
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